Otsuka Holdings Co., Ltd.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Makoto Inoue
- Full Time Employees
- 37,758
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 2-9 Kanda-Tsukasamachi Tokyo TKY Japan 101-0048
- IPO Date
- Dec 15, 2010
- Website
- otsuka.com
- Similar Companies
- Business
- Otsuka Holdings Co., Ltd. operates as a global healthcare enterprise with diverse interests across pharmaceutical, nutraceutical, consumer product, and additional business segments around the world. Within its core pharmaceutical operations, the company is dedicated to researching, developing, manufacturing, and marketing innovative therapies for conditions affecting the central nervous system, including treatments for schizophrenia and bipolar disorder. Other significant therapeutic areas encompass oncology, cardiovascular and renal systems, infectious diseases, and ophthalmology, supported by offerings in diagnostics and intravenous solutions. Notably, the company recently launched NEXLETOL in Japan and secured a positive CHMP opinion for Donidalorsen in hereditary angioedema. The nutraceutical division focuses on science-based functional foods and beverages that promote everyday health. Prominent products include the rehydration solution POCARI SWEAT, the nutritional block food Calorie Mate, the vitamin drink ORONAMIN C, and the soy-based snack SOYJOY, alongside solutions for women's health like EQUELLE. Beyond these, Otsuka's consumer offerings extend to various beverages and food items. Its "other businesses" portfolio includes chemicals, specialized medical equipment, cosmetics, warehousing and transportation services, and advanced analytical instrumentation. Established in Tokyo, Japan, in 1921, Otsuka Holdings is committed to original value creation and addressing global health challenges through its integrated approach.
Company News
Otsuka (OTCMKTS:OTSKY) Shares Gap Down – Here’s Why
Critical Survey: Inhibikase Therapeutics (NASDAQ:IKT) and Otsuka (OTCMKTS:OTSKY)
Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatment
Otsuka Holdings Co., Ltd. (OTSKY) Discusses 24-Month eGFR Results of Sibeprenlimab in IgA Nephropathy from Phase III VISIONARY Study Prepared Remarks Transcript
Otsuka Holdings Co., Ltd. (OTSKY) Q2 2026 Earnings Call Prepared Remarks Transcript
Aristotle Global Equity Advisory Q2 2026 Portfolio Review
Otsuka ICU Medical LLC Announces Over $500M Expansion of IV Solutions Manufacturing in North America
Aristotle International Equity ADR WM Q1 2026 Contributors And Detractors
AstraZeneca (OTCMKTS:AZNCF) versus Otsuka (OTCMKTS:OTSKY) Financial Review
Otsuka Holdings Co., Ltd. (OTSKY) M&A Call Prepared Remarks Transcript
Santen Pharmaceutical (OTCMKTS:SNPHY) & Otsuka (OTCMKTS:OTSKY) Financial Review
Contrasting Otsuka (OTCMKTS:OTSKY) and Mayne Pharma Group (OTCMKTS:MAYNF)
Otsuka Holdings Co., Ltd. (OTSKY) Q4 2025 Earnings Call Prepared Remarks Transcript
Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer
Otsuka (OTCMKTS:OTSKF) Trading Up 3% – Should You Buy?
Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST
Recent Price Trend in Otsuka Holdings Co., Ltd. - Unsponsored ADR (OTSKY) is Your Friend, Here's Why
Otsuka Holdings Co., Ltd. - Unsponsored ADR (OTSKY) Is a Great Choice for 'Trend' Investors, Here's Why
Here's Why Momentum in Otsuka Holdings Co., Ltd. - Unsponsored ADR (OTSKY) Should Keep going